GSK Of U.K. To Put $100 Million Into R&D Center For Neuroscience Center (China)
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline plans to develop a $100 million neuroscience research center in China as a key element in its global drug-development strategy. The company's research-and-development head said the intention is to have the center be responsible for all work on neuro-degenerative diseases for treating diseases such as Alzheimer's, Parkinson's and multiple sclerosis. Moncef Sioui said GSK no longer sees China as an outsourcing and cheap-labor center, but now one capable of "different science." Several other global drug firms also are eying significant R&D investments in China. (Click here for more ) "GSK In $100 Million China Push" Financial Times (U.K.) (12/13/07)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.